Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon

Related Experiment Video

Updated: Nov 28, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Sarubala Malayaperumal1, Sushmitha Sriramulu1, Antara Banerjee1

  • 1Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Chennai 603103, Tamil Nadu, India.

Current Pharmaceutical Biotechnology
|November 27, 2020
PubMed
Abstract

Insights

Colon cancer remains a significant global health challenge. While neoadjuvant chemoradiotherapy shows promise, current therapies are insufficient, necessitating research into novel biotechnological treatments for improved survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Colon cancer is a leading cause of cancer deaths globally, with 1.2 million new cases annually.
  • Conventional treatments are being supplanted by targeted therapies due to advances in molecular biology.

Purpose of the Study:

  • To review conventional colon cancer therapies and compare their effectiveness on overall survival.
  • To explore next-generation biotechnological therapeutics for colon cancer treatment.

Main Methods:

  • Comparative analysis of existing conventional therapies for colon cancer.
  • Review of emerging biotechnologies including nucleic acid medicines, CRISPR-Cas9, adoptive cell therapy, cancer stem cell therapy, gut microbiome, and personalized medicine.

Main Results:

  • Neoadjuvant chemoradiotherapy demonstrated safety and efficacy in improving overall survival for resected colon cancer patients.
  • Current conventional therapies are not significantly improving overall survival, indicating a need for further research.

Conclusions:

  • Existing colon cancer treatments are insufficient for improving overall survival.
  • Biotechnological next-generation therapeutics offer promising alternative approaches.
  • Multi-disciplinary strategies are essential for developing tailored colon cancer treatments.
Keywords:
Conventionalchemoradiotherapycolon canceroverall survivalpersonalized medicine.therapeutics

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
697
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
328
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
908
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K